QingSong Health Corporation Announces Strategic Cooperation Memorandum of Understanding with BMGL
Overview
QingSong Health Corporation, a digital health enterprise listed on the Hong Kong Stock Exchange (Stock Code: 2661), has made a voluntary announcement regarding a major business development. The company has entered into a three-year Memorandum of Understanding (MOU) for strategic cooperation with Basel Medical Group Ltd (BMGL), a medical services group listed on Nasdaq and headquartered in Singapore.
Key Points of the Announcement
- Date of MOU: 10 June 2026 (after trading hours)
- Nature of Cooperation: The partnership aims to leverage QingSong’s proprietary medical AI technologies (QSevidence, MedClaw medical AI consortium system, and AIcare technology stack) together with BMGL’s clinical expertise and market access in Southeast Asia.
- Strategic Objectives: The cooperation will focus on two-way development of technology output and iteration, with a view to upgrading healthcare services in Southeast Asia and exploring new market opportunities.
- Parties Involved:
- QingSong Health Corporation: Specializes in evidence-based AI medical solutions and has operational experience in the health insurance value chain.
- BMGL: Clinical competencies in orthopedics, trauma, sports medicine, neurosurgery, and a strong corporate client network in Southeast Asia, especially in industries with high occupational health exposure.
- Independence: BMGL and its ultimate beneficial owners are independent third parties and not connected with QingSong Health or its connected persons.
Detailed Cooperation Areas
Operational Level: Enhancing Intelligence in BMGL’s Business
- Physician Training: QingSong’s evidence-based AI capabilities will provide sustainable clinical decision support and training to BMGL’s medical teams, potentially improving clinical outcomes and efficiency.
- Patient Customer Services: The use of conversational AI will optimize the patient experience throughout all stages, from appointment booking to consultations and follow-ups, raising service standards and patient satisfaction.
- Insurance Claims: AI will be applied to claims processing and underwriting, enhancing evidence-based standards across BMGL’s insurance value chain, with a focus on clients in high-risk industries such as construction, maritime, and oil & gas.
Growth Level: Joint Exploration of New Markets
- Cross-Border Health Services: The companies aim to establish a health services corridor between China and Southeast Asia, utilizing QingSong’s cross-border health service capabilities and BMGL’s Singapore hub to tap into specialist networks across the region.
Potential Impact on Shareholders and Share Price
This MOU marks a significant milestone in QingSong Health’s overseas expansion and application of its AI agent technology. It is expected to accelerate the company’s technological iteration, broaden business opportunities by leveraging diverse clinical and service settings in Southeast Asia, and strengthen QingSong’s competitive edge in medical AI. The partnership also aligns with the company’s long-term strategy for technology and business development. While this MOU does not create legally binding obligations (except for confidentiality), the strategic intent and potential for technological and market breakthroughs may be price sensitive and could positively influence QingSong’s value proposition for shareholders. Investors should take note of the early-stage nature of this agreement and exercise caution when dealing in the shares.
Board Composition
As of the announcement date, the Board comprises Ms. YANG Yin (Chairlady, Executive Director & CEO), Mr. ZHAO Yuping, Mr. ZHENG Kaihuan, and Mr. WU Bin (Non-executive Directors), as well as Dr. WANG Xiaoyan, Mr. CHOW Yiu Ming, and Ms. JI Wenting (Independent Non-executive Directors).
Disclaimer
This article is for informational purposes only and does not constitute investment advice. The Memorandum of Understanding described herein is not legally binding except for confidentiality provisions. Shareholders and potential investors are advised to exercise caution and consult professional advisers before making any investment decisions regarding the shares of QingSong Health Corporation.
輕鬆健康集團宣佈與BMGL簽署三年戰略合作備忘錄
概述
輕鬆健康集團（香港交易所上市，股份代號：2661）自願發佈重大業務發展公告，公司與新加坡總部、納斯達克上市的巴塞爾醫療集團（BMGL）簽署為期三年的戰略合作備忘錄（MOU）。
公告重點
- 簽署日期：2026年6月10日（收市後）
- 合作性質：雙方將結合輕鬆健康自研醫療AI技術（QSevidence、MedClaw醫療AI聯盟系統及AIcare技術棧），與BMGL的臨床專業與東南亞市場渠道，推動區域醫療服務智能升級及市場拓展。
- 戰略目標：實現技術輸出與迭代雙向發展，把握東南亞醫療市場新機遇。
- 合作方：
- 輕鬆健康集團：專精證據為本AI醫療方案，具備健康保險價值鏈運營經驗。
- BMGL：擁有骨科、創傷、運動醫學、神經外科臨床能力，並於東南亞建立多年企業客戶網絡，尤其涉及高職業健康風險行業。
- 獨立性：BMGL及其最終實益擁有人均為獨立第三方，與輕鬆健康及其關聯人士無關。
合作詳情
營運層面：提升BMGL現有業務智能化
- 醫生培訓：利用輕鬆健康的證據為本AI能力，為BMGL臨床團隊提供持續的臨床決策支持與培訓，提升醫療質素及效率。
- 患者服務：運用對話式AI，優化患者從預約、診療到跟進的全流程體驗，提升服務標準與病人滿意度。
- 保險理賠：應用AI於理賠處理及承保判斷，提升保險價值鏈證據標準重點服務於建築、航運、石油及天然氣等高職業健康風險客戶。
增長層面：共同探索新市場
- 跨境健康服務：雙方將依托輕鬆健康的跨境健康服務能力及BMGL新加坡區域樞紐地位，共同建立連接中國與東南亞專科網絡的健康服務走廊。
對股東及股價的潛在影響
此備忘錄標誌著輕鬆健康集團AI技術海外應用場景探索的重要里程碑，預期將加速技術迭代，藉東南亞多元臨床及服務場景擴展業務機會，鞏固集團在醫療AI領域競爭優勢。此舉與集團長遠科技及業務發展策略相符，對股東利益具正面作用。 雖然備忘錄除保密條款外並無法律約束力，但合作意向及未來技術、市場突破潛力具價格敏感性，有機會正面影響股價。投資者須注意協議仍屬初步意向，操作股份時請謹慎。
董事會組成
截至公告日，董事會包括：楊寅（主席、執行董事兼首席執行官）、趙玉平、鄭凱歡、吳斌（非執行董事）、王小燕博士、周耀明、紀文婷（獨立非執行董事）。
免責聲明
本文僅供資訊參考，並不構成任何投資建議。上述備忘錄除了保密條款外並無法律約束力。股東及潛在投資者應謹慎行事，並諮詢專業顧問後再作出有關輕鬆健康股份的投資決定。
